Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Authors
Keywords
-
Journal
Epigenetics
Volume 9, Issue 11, Pages 1511-1520
Publisher
Informa UK Limited
Online
2014-12-07
DOI
10.4161/15592294.2014.983367
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas
- (2015) Wilko Weichert et al. NEOPLASIA
- Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC
- (2013) Sridurga Mithraprabhu et al. BRITISH JOURNAL OF HAEMATOLOGY
- HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity
- (2013) Gang Ding et al. FEBS LETTERS
- The functional interactome landscape of the human histone deacetylase family
- (2013) P. Joshi et al. Molecular Systems Biology
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance
- (2012) Michaël Van Damme et al. Epigenetics
- HDAC11 is a novel drug target in carcinomas
- (2012) Hedwig E. Deubzer et al. INTERNATIONAL JOURNAL OF CANCER
- Histone deacetylases and cancer
- (2012) Bruna Barneda-Zahonero et al. Molecular Oncology
- Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis
- (2011) Andrea Clocchiatti et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms
- (2011) Vibe Skov et al. LEUKEMIA & LYMPHOMA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
- (2010) J. Kikuchi et al. BLOOD
- research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia
- (2010) Daniel Antunes Moreno et al. BRITISH JOURNAL OF HAEMATOLOGY
- The DAC system and associations with multiple myeloma
- (2010) Enrique M. Ocio et al. INVESTIGATIONAL NEW DRUGS
- The Role of HDAC6 in Cancer
- (2010) Grace I. Aldana-Masangkay et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Regulating the Regulators: The Post-Translational Code of Class I HDAC1 and HDAC2
- (2010) Chiara V. Segré et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas
- (2009) Lena Marquard et al. HISTOPATHOLOGY
- Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors
- (2009) Taeko Wada et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- HDAC expression and clinical prognosis in human malignancies
- (2008) Wilko Weichert CANCER LETTERS
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo
- (2008) W. Weichert et al. CLINICAL CANCER RESEARCH
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- Enhanced histone deacetylase enzyme activity in primary myelofibrosis
- (2008) Jen Chin Wang et al. LEUKEMIA & LYMPHOMA
- HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
- (2008) Andrew J. Wilson et al. MOLECULAR BIOLOGY OF THE CELL
- The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
- (2008) Alejandro Villagra et al. NATURE IMMUNOLOGY
- The many roles of histone deacetylases in development and physiology: implications for disease and therapy
- (2008) Michael Haberland et al. NATURE REVIEWS GENETICS
- HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism
- (2008) D Mottet et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started